NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT01322490 2019-09-04
Prospect
Bavarian Nordic
Phase 3 Completed
NCT01875653 2019-05-10
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Lisata Therapeutics, Inc.
Phase 3 Terminated
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT01479244 2017-02-27
PRESENT
Galena Biopharma, Inc.
Phase 3 Completed
NCT00769704 2016-07-13
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
BioVex Limited
Phase 3 Completed
NCT01368276 2015-12-18
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
BioVex Limited
Phase 3 Completed
NCT00091676 2012-02-03
BiovaxID
Biovest International
Phase 3 Unknown